Alessandro Gianni
Alessandro Gianni
Verified email at
TitleCited byYear
Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli
M Di Nicola, C Carlo-Stella, M Magni, M Milanesi, PD Longoni, ...
Blood, The Journal of the American Society of Hematology 99 (10), 3838-3843, 2002
Granulocyte-macrophage colony-stimulating factor to harvest circulating haemopoietic stem cells for autotransplantation
AM Gianni, M Bregni, AC Stern, S Siena, C Tarella, A Pileri, G Bonadonna
The Lancet 334 (8663), 580-585, 1989
Flow cytometry for clinical estimation of circulating hematopoietic progenitors for autologous transplantation in cancer patients
S Siena, M Bregni, B Brando, N Belli, F Ravagnani, L Gandola, AC Stern, ...
High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma
AM Gianni, M Bregni, S Siena, C Brambilla, M Di Nicola, F Lombardi, ...
New England Journal of Medicine 336 (18), 1290-1298, 1997
Circulation of CD34+ hematopoietic stem cells in the peripheral blood of high-dose cyclophosphamide-treated patients: enhancement by intravenous recombinant human granulocyte …
S Siena, M Bregni, B Brando, F Ravagnani, G Bonadonna, AM Gianni
Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a …
CH Moskowitz, A Nademanee, T Masszi, E Agura, J Holowiecki, MH Abidi, ...
The Lancet 385 (9980), 1853-1862, 2015
Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type
A Conconi, G Martinelli, C Thiéblemont, AJM Ferreri, L Devizzi, ...
Blood 102 (8), 2741-2745, 2003
ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned
S Viviani, PL Zinzani, A Rambaldi, E Brusamolino, A Levis, V Bonfante, ...
New England Journal of Medicine 365 (3), 203-212, 2011
Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin's lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic …
P Corradini, A Dodero, F Zallio, D Caracciolo, M Casini, M Bregni, F Narni, ...
Journal of Clinical Oncology 22 (11), 2172-2176, 2004
Successful in vivo purging of CD34-containing peripheral blood harvests in mantle cell and indolent lymphoma: evidence for a role of both chemotherapy and rituximab infusion
M Magni, M Di Nicola, L Devizzi, P Matteucci, F Lombardi, L Gandola, ...
Blood, The Journal of the American Society of Hematology 96 (3), 864-869, 2000
Massive ex vivo generation of functional dendritic cells from mobilized CD34+ blood progenitors for anticancer therapy.
S Siena, MN Di, M Bregni, R Mortarini, A Anichini, L Lombardi, ...
Experimental hematology 23 (14), 1463-1471, 1995
Induction of cyclophosphamide-resistance by aldehyde-dehydrogenase gene transfer
M Magni, S Shammah, R Schiro, W Mellado, R Dalla-Favera, AM Gianni
Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen)
AM Gianni, M Magni, M Martelli, M Di Nicola, C Carlo-Stella, S Pilotti, ...
Blood 102 (2), 749-755, 2003
A phase 1/2 trial of arginine butyrate and ganciclovir in patients with Epstein-Barr virus–associated lymphoid malignancies
SP Perrine, O Hermine, T Small, F Suarez, R O'Reilly, F Boulad, ...
Blood 109 (6), 2571-2578, 2007
Long-term follow-up of patients with peripheral T-cell lymphomas treated up-front with high-dose chemotherapy followed by autologous stem cell transplantation
P Corradini, C Tarella, F Zallio, A Dodero, M Zanni, P Valagussa, ...
Leukemia 20 (9), 1533-1538, 2006
Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis …
M Ladetto, F De Marco, F Benedetti, U Vitolo, C Patti, A Rambaldi, ...
Blood, The Journal of the American Society of Hematology 111 (8), 4004-4013, 2008
Primary diffuse large B-cell lymphoma of the breast: prognostic factors and outcomes of a study by the International Extranodal Lymphoma Study Group
G Ryan, G Martinelli, M Kuper-Hommel, R Tsang, G Pruneri, K Yuen, ...
Annals of oncology 19 (2), 233-241, 2008
Recombinant human granulocyte-macrophage colony-stimulating factor reduces hematologic toxicity and widens clinical applicability of high-dose cyclophosphamide treatment in …
AM Gianni, M Bregni, S Siena, A Orazi, AC Stern, L Gandola, ...
Journal of Clinical Oncology 8 (5), 768-778, 1990
Efficacy, toxicity, and applicability of high-dose sequential chemotherapy as adjuvant treatment in operable breast cancer with 10 or more involved axillary nodes: five-year …
AM Gianni, S Siena, M Bregni, M Di Nicola, S Orefice, F Cusumano, ...
Journal of clinical oncology 15 (6), 2312-2321, 1997
An expanded peripheral T cell population to a cytotoxic T lymphocyte (CTL)-defined, melanocyte-specific antigen in metastatic melanoma patients impacts on generation of peptide …
A Anichini, A Molla, R Mortarini, G Tragni, I Bersani, M Di Nicola, ...
The Journal of experimental medicine 190 (5), 651-668, 1999
The system can't perform the operation now. Try again later.
Articles 1–20